Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Oncologic Drugs Advisory Committee

Executive Summary

Oncologic Drugs Advisory Committee: At its June 8-9 meeting, the committee will review Rhone-Poulenc Rorer's Taxotere (docetaxel) for patients with locally advanced or metastatic breast carcinoma in whom previous therapy has failed and NeXstar's liposomal daunorubicin DaunoXome on June 8 ("The Pink Sheet" April 17, T&G-1). The committee recommended against approval of Taxotere based on Phase II data Dec. 12 ("The Pink Sheet" Dec. 19, 1994, p. 7). On June 9, the committee will review U.S. Bioscience's Ethyol (amifostine injection) for the cumulative renal toxicity associated with cisplatin and the cumulative hematologic toxicity of cyclophosphamide and cisplatin. The committee found the drug needed further study in recommending against approval Dec. 12 at Ethyol's second advisory committee review ("The Pink Sheet" Dec. 19, 1994, p. 11)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel